SLNSW-Phase 1b study of galunisertib and ramucirumab in...-TN_cdi_doaj_primary_oai_doaj_org_article_a3e937bb75b74d4cbd5609cb1c0768da

Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma

Full title: Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma

Author/creator: Harding, James J., Do, Richard K., Yaqubie, Amin, Cleverly, Ann, Zhao, Yumin, Gueorguieva, Ivelina, Lahn, Michael, Benhadji, Karim A., Kelley, Robin K., Abou‐Alfa, Ghassan K..

Call Numbers:

Record Identifier: TN_cdi_doaj_primary_oai_doaj_org_article_a3e937bb75b74d4cbd5609cb1c0768da

Language: English

Formats: Articles

Publishers: United States: Wiley Subscription Services, Inc

Permalink: https://collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_a3e937bb75b74d4cbd5609cb1c0768da

Articles

Articles

Export this record

Export selected records

  • Export to excel
  • Permalink

    • Export record to excel

    File type to download

    Beta version

    Record title

    Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma

    Record identifier

    TN_cdi_doaj_primary_oai_doaj_org_article_a3e937bb75b74d4cbd5609cb1c0768da

    Record permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_a3e937bb75b74d4cbd5609cb1c0768da

    Share

    Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma

    ACCESS
    https://collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_a3e937bb75b74d4cbd5609cb1c0768da

    Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma

    Full title

    Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma

    Author / Creator

    Harding, James J. ; Do, Richard K. ; Yaqubie, Amin ; Cleverly, Ann ; Zhao, Yumin ; Gueorguieva, Ivelina ; Lahn, Michael ; Benhadji, Karim A. ; Kelley, Robin K. ; Abou‐Alfa, Ghassan K.

    Publisher

    United States: Wiley Subscription Services, Inc

    Journal title

    Cancer medicine (Malden, MA), 2021, Vol.10 (9), p.3059-3067

    Record Identifier

    TN_cdi_doaj_primary_oai_doaj_org_article_a3e937bb75b74d4cbd5609cb1c0768da

    Language

    English

    Formats

    Articles

    Publication information

    Publisher

    Subjects

    Subjects and topics

    Adverse events Aged Aged, 80 and over alpha-Fetoproteins - analysis Angiogenesis Antibodies Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - pharmacokinetics Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacokinetics Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antitumor activity Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - metabolism Carcinoma, Hepatocellular - pathology Care and treatment Clinical Cancer Research Complications and side effects Development and progression Disease control Drug dosages Enrollments Female galunisertib Glycoproteins HCC Hepatocellular carcinoma Hepatoma Humans Hypertension Immune response Immunotherapy Kinases Liver cancer Liver Neoplasms - drug therapy Liver Neoplasms - metabolism Liver Neoplasms - pathology Male Maximum Tolerated Dose Medical prognosis Medical research Medicine, Experimental Middle Aged Monoclonal antibodies Nausea Nausea - chemically induced Original Research Patients Pharmacokinetics Phase 1 Prospective Studies Pyrazoles - administration & dosage Pyrazoles - adverse effects Pyrazoles - pharmacokinetics Quinolines - administration & dosage Quinolines - adverse effects Quinolines - pharmacokinetics ramucirumab Receptor, Transforming Growth Factor-beta Type I - antagonists & inhibitors Response Evaluation Criteria in Solid Tumors Stroke Stroke (Disease) TGF‐β Transforming growth factors Vascular endothelial growth factor Vascular Endothelial Growth Factor A - metabolism Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors VEGF Viral antibodies Vomiting Vomiting - chemically induced

    More information

    — SCOPE AND CONTENTS

    Contents

    — ALTERNATIVE TITLES

    Full title

    — AUTHORS, ARTISTS AND CONTRIBUTORS

    Author / Creator

    Identifiers

    — PRIMARY IDENTIFIERS

    Record Identifier

    TN_cdi_doaj_primary_oai_doaj_org_article_a3e937bb75b74d4cbd5609cb1c0768da

    Permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_a3e937bb75b74d4cbd5609cb1c0768da

    — OTHER IDENTIFIERS

    ISSN

    E-ISSN

    DOI

    How to access this item

    Online

    1 item

    How to access?

    Login with a Library card

    Full text available >

    About resource >

    View in old catalogue

    Connecting people and collections